TEK and gastrointestinal stromal tumor: It targets different angiogenic (vascular endothelial growth factor receptor (VEGFR)-1, -2, and -3, and angiopoietin-1 receptor (TIE2)), oncogenic (KIT, Ret protooncogene, RAF-1 protooncogene, BRAF, and BRAFV600E), and stromal (PDGFR and fibroblast growth factor receptor (FGFR)) TKs with noticeable survival benefits in patients with advanced GIST resistant to IM and SM [14].